重新发明一个更好的轮子? 塞普鲁利马布用于平细胞肺癌
Derek De-Rui Huang1, James Chih-Hsin Yang2
1Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Cancer cell
|February 13, 2024
概括
一线塞尔普鲁利马布加化疗对晚期状非小细胞肺癌 (NSCLC) 具有前途. 这种化疗免疫治疗方案为患有这种具有挑战性的NSCLC亚型的患者提供了新的有效治疗选择.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 胸部癌症 胸部癌症 乳腺癌
背景情况:
- 免疫检查点抑制剂已经彻底改变了癌症治疗.
- 有限的临床试验重点是针对状非小细胞肺癌 (NSCLC) 的化疗免疫疗法.
研究的目的:
- 为了评估塞普鲁利马布与化疗相结合的疗效,作为先进状NSCLC的第一线治疗.
主要方法:
- 一项临床试验调查了先进状NSCLC患者的塞普卢利马布和化疗的组合.
- 评估治疗反应和患者的治疗结果.
主要成果:
- 塞普鲁利马布加化学疗法作为一线治疗显示出显著的有效性.
- 组合治疗方案为晚期状NSCLC提供了可行的治疗选择.
结论:
- 用塞尔普卢利马布和化疗进行的第一线化疗免疫治疗对晚期状NSCLC有效.
- 这种方法解决了治疗这种特定NSCLC亚型的未满足需求.
更多相关视频
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
10.6K
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.5K
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...